Presenter: Bernard Combe, Montpellier University, France.
Wednesday 12 June: 16:15–17:45 (Abstract LB0001)
FINCH 1 is a phase III randomized trial in which 1759 participants with moderate-to-severe rheumatoid arthritis and an inadequate response to methotrexate were randomly assigned to receive the Janus kinase I inhibitor filgotinib, placebo, or the active comparator adalimumab, all given in combination with methotrexate. The primary outcome is the proportion of patients with an ACR20 response at week 12.
- News story | Support for filgotinib use in RA patients with inadequate response to methotrexate
- Researcher comment | WATCH: The lead investigator discusses the findings
- Expert commentary | WATCH: Roy Fleischmann discusses the results
- Expert commentary | WATCH: John Isaacs discusses the FINCH 1 and FINCH 3 results
- External link | Conference abstract
- External link | ClinicalTrials.gov registration page
- Quick guide | JAK inhibitors in RA: A round-up of the phase III trials